参考文献/References:
[1]米荷音,李悦,郝咏刚,等.偏头痛与脑小血管病MRI总负荷评分的相关性研究[J].放射学实践,2019,34(4):386-391.[2]郭丰,任占秀,何秋,等.偏头痛发作期患者血浆HCY和CRP含量及其相关性研究[J].中风与神经疾病杂志,2015,32(3):225-227.[3]王思博,刘亢丁,杨弋,等.中国偏头痛患者右向左分流阳性率及分流类型——一项全国多中心研究[J].中国卒中杂志,2018,13(3):251-256.[4]张成林,刘东,严妤函,等.探讨偏头痛大鼠三叉神经节内可能调控CGRP表达的微小RNA[J].中国疼痛医学杂志,2015,21(10):738-744.[5]董晓梦,荆龙,陈金波.偏头痛模型大鼠相关活性物质表达[J].中国神经免疫学和神经病学杂志,2015,22(1):34-39,45.[6]Demarquay G,Moisset X.CGRP et migraine:ce qu’il faut savoir en 2020[J].Douleur et Analgésie,2020,33(3):127-135.[7]张伟,李爱红.盐酸氟桂利嗪联合阿司匹林对偏头痛患者临床症状及血管活性因子的影响[J].中南医学科学杂志,2018,46(4):428-430.[8]王健昌.阿司匹林联合尼莫地平治疗偏头痛的临床疗效观察[J].中国执业药师,2016,13(10):6-9.[9]李伟,徐翠萍,陈敏,等.阿司匹林与尼莫地平治疗偏头痛临床对比研究[J].河北医学,2015,21(1):160-163.[10]展波涛.舒马曲坦联合左乙拉西坦治疗顽固性偏头痛的疗效及对血浆5-羟色胺水平的影响[J].药品评价,2020,17(14):31-32,35.[11]吕春翔.利扎曲普坦与舒马普坦治疗偏头痛的临床对照[J].黑龙江科学,2019,10(8):42-43.[12]秦娜,李力,陈璇,等.舒马曲坦联合左乙拉西坦治疗顽固性偏头痛的疗效及对血浆5-羟色胺的影响[J].医学临床研究,2017,34(11):2255-2257.[13]雷靖华.桃红饮加味合麦角胺治疗偏头痛46例临床观察[J].湖南中医杂志,2016,32(10):62-64.[14]Robblee JV,Butterfield RJ,Kang AM,et al.Triptan and ergotamine overdoses in the United States:Analysis of the National Poison Data System[J].Neurology,2020,94(14):e1460-e1469.[15]曹琪璐,刘菁,赵彤,等.氟西汀对PC12细胞缺氧损伤的保护作用[J].中国药理学通报,2021,37(6):866-870.[16]Kuca B,Silberstein SD,Wietecha L,et al.Lasmiditan is an effective acute treatment for migraine:a phase 3 randomized study[J].Neurology,2018,91(24):e2222-e2232.[17]王淑丽,牛争平,周芸,等.偏头痛患者降钙素基因相关肽与局部脑血流量变化的相关研究[J].中华神经医学杂志,2015,14(9):950-954.[18]Martelletti P,Giamberardino MA.Advances in orally administered pharmacotherapy for the treatment of migraine[J].Expert Opin Pharmacother,2019,20(2):209-218.[19]Croop R,Goadsby PJ,Stock DA,et al.Efficacy,safety,and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine:a randomised,phase 3,double-blind,placebo-controlled trial[J].Lancet,2019,394(10200):737-745.[20]余鸽鸽,严澎,柳平,等.酒石酸美托洛尔联合氟桂利嗪治疗偏头痛的效果观察[J].中国合理用药探索,2019,16(12):31-33,36.[21]张光远.普萘洛尔联合氟桂利嗪预防性治疗偏头痛患者的临床疗效[J].中国药物经济学,2016,11(3):84-86.[22]龚雪琴,张娟.酒石酸美托洛尔联合氟桂利嗪预防性治疗偏头痛的疗效观察[J].中西医结合心脑血管病杂志,2016,14(24):2957-2959.[23]郑智慧.尼莫地平联合氟桂利嗪对血管神经性头痛的疗效观察[J].深圳中西医结合杂志,2021,31(6):176-177.[24]李艳芳,谢广迪.阿司匹林与尼莫地平治疗偏头痛患者的有效性对照比较[J].临床合理用药杂志,2021,14(17):45-46.[25]范桂梅,芮汉臣,李广从,等.氟桂利嗪联合尼莫地平治疗偏头痛患者效果及对脑血流动力学影响[J].临床误诊误治,2021,34(11):40-43. [26]胡建军.托吡酯对神经性偏头痛的治疗作用[J].中国药物经济学,2020,15(7):84-86,89.[27]张钊勇,萧云,万里飞.托吡酯对神经性偏头痛患者神经元放电及脑血流的影响[J].河北医药,2019,41(5):762-764.[28]Goadsby PJ,Reuter U,Hallstrom Y,et al.A Controlled Trial of Erenumab for Episodic Migraine[J].The New England Journal of Medicine,2017,377(22):2123-2132.[29]Detke HC,Peter J,et al.Galcanezumab in chronic migraine:The randomized,double-blind,placebo-controlled REGAIN study[J].Neurology,2018,91(24):e2211-e2221.[30]Smith J,Dodick DW,Goadsby PJ,et al.Randomized,Double-blind,Placebo-controlled Trial of ALD403,an anti-CGRP peptide antibody in the prevention of chronic migraine[J].Cephalal-gia,2016,56(8):1391．[31]Silberstein SD,Dodick DW,Bigal ME,et al.Fremanezumab for the preventive treatment of chronic migraine[J].The New England Journal of Medicine,2017,377(22):2113-2122.[32]Camporeale A,Kudrow D,Sides R,et al.A phase 3,long-term,open-label safety study of Galcanezumab in patients with migraine[J].BMC Neurology,2018,18(1):188.
相似文献/References:
[1]罗会义.脑梗死抑郁的发作因素及临床治疗研究[J].医学信息,2018,31(04):181.[doi:10.3969/j.issn.1006-1959.2018.04.069]
LUO Hui-yi.A Study on the Attack Factors and Clinical Treatment of Depression in Cerebral Infarction[J].Medical Information,2018,31(09):181.[doi:10.3969/j.issn.1006-1959.2018.04.069]
[2]吕桂英.影响糖尿病患者药物治疗依从性相关因素临床分析[J].医学信息,2018,31(08):109.[doi:10.3969/j.issn.1006-1959.2018.08.036]
LV Gui-ying.Clinical Analysis of Factors Related to Compliance with Drug Therapy in Patients with Diabetes Mellitus[J].Medical Information,2018,31(09):109.[doi:10.3969/j.issn.1006-1959.2018.08.036]
[3]刘 洁.糖尿病药物治疗的现状及研究进展[J].医学信息,2022,35(09):69.[doi:10.3969/j.issn.1006-1959.2022.09.017]
LIU Jie.Current Situation and Research Progress of Diabetic Drug Therapy[J].Medical Information,2022,35(09):69.[doi:10.3969/j.issn.1006-1959.2022.09.017]
[4]王跃慧.急性缺血性脑卒中的药物治疗[J].医学信息,2022,35(11):44.[doi:10.3969/j.issn.1006-1959.2022.11.013]
WANG Yue-hui.Drug Treatment of Acute Ischemic Stroke[J].Medical Information,2022,35(09):44.[doi:10.3969/j.issn.1006-1959.2022.11.013]
[5]王煜婷.原发性痛经发病机制及口服药物治疗进展[J].医学信息,2018,31(13):56.[doi:10.3969/j.issn.1006-1959.2018.13.016]
WANG Yu-ting.Research Progress in Pathogenesis and Oral Medication of Primary Dysmenorrhea[J].Medical Information,2018,31(09):56.[doi:10.3969/j.issn.1006-1959.2018.13.016]
[6]彭莹萍.尼莫地平与盐酸氟桂利嗪治疗老年偏头痛的临床疗效观察[J].医学信息,2018,31(22):150.[doi:10.3969/j.issn.1006-1959.2018.22.044]
PENG Ying-ping.Clinical Efficacy of Nimodipine and Flunarizine Hydrochloride in the Treatment of Senile Migraine[J].Medical Information,2018,31(09):150.[doi:10.3969/j.issn.1006-1959.2018.22.044]
[7]高 翔,夏 亮,杨亚斌.原发性闭角型青光眼的治疗[J].医学信息,2018,31(23):51.[doi:10.3969/j.issn.1006-1959.2018.23.015]
GAO Xiang,XIA Liang,YANG Ya-bin.Treatment of Primary Angleclosure Glaucoma[J].Medical Information,2018,31(09):51.[doi:10.3969/j.issn.1006-1959.2018.23.015]
[8]杨国锋,钱朝庆,白文伟.介入术后冠脉无复流的危险因素识别与药物治疗[J].医学信息,2019,32(04):44.[doi:10.3969/j.issn.1006-1959.2019.04.016]
YANG Guo-fen,QIAN Chao-qing,BAI Wen-wei.Identification of Risk Factors and Drug Therapy for Postoperative Coronary Artery No-reflow[J].Medical Information,2019,32(09):44.[doi:10.3969/j.issn.1006-1959.2019.04.016]
[9]杨 震.急性心梗直接介入治疗术中慢血流及无复流的治疗进展[J].医学信息,2019,32(06):56.[doi:10.3969/j.issn.1006-1959.2019.06.19]
YANG Zhen.Progress in the Treatment of Slow Blood Flow and no Reflow in the Treatment of Acute Myocardial Infarction[J].Medical Information,2019,32(09):56.[doi:10.3969/j.issn.1006-1959.2019.06.19]
[10]吴 旭,张美英.2型糖尿病患者合并焦虑抑郁状况研究[J].医学信息,2019,32(08):78.[doi:10.3969/j.issn.1006-1959.2019.08.023]
WU Xu,ZHANG Mei-ying.Research on Anxiety and Depression in Patients with Type 2 Diabetes[J].Medical Information,2019,32(09):78.[doi:10.3969/j.issn.1006-1959.2019.08.023]